BMRN:NSD-BioMarin Pharmaceutical Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 82.97

Change

0.00 (0.00)%

Market Cap

USD 15.06B

Volume

1.31M

Average Target Price

USD 124.15 (+49.63%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide, a peptide therapeutic that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; and BMN 307, an AAV5 mediated gene therapy to normalize blood phenylalanine concentration levels in patients with phenylketonuria. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd.; and a preclinical collaboration and license agreement with DiNAQOR AG for the development of gene therapies to treat rare genetic cardiomyopathies. The company was founded in 1996 and is headquartered in San Rafael, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD58.65B 22.10 18.26
REGN Regeneron Pharmaceuticals, Inc

N/A

USD55.27B 18.98 14.09
MRNA Moderna, Inc

N/A

USD51.30B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD34.27B 36.37 33.83
SGEN Seagen Inc

N/A

USD33.25B 70.15 66.51
RPRX Royalty Pharma plc

N/A

USD32.48B 22.60 11.76
BGNE BeiGene, Ltd

N/A

USD31.24B N/A N/A
GMAB Genmab A/S

N/A

USD28.71B 26.59 3.08
BNTX BioNTech SE

N/A

USD24.46B -99,999.99 N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BMRN

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

N/A

USD0.48B
GNOM Global X Genomics & Biote.. 0.00 % 0.50 %

N/A

USD0.11B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

USD0.03B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
QDVC:F iShares Edge MSCI USA Siz.. 0.00 % 0.20 %

N/A

USD0.12B
ETLI:F L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

USD0.03B
IUSF:LSE iShares Edge MSCI USA Siz.. 0.00 % 0.20 %

N/A

USD0.09B
BIOT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

USD8.18M
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

USD0.02B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.27B
EASI Amplify EASI Tactical Gro.. 0.00 % 0.81 %

N/A

USD0.01B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

N/A

USD0.03B
USLB Invesco Russell 1000 Low .. 0.00 % 0.35 %

N/A

USD8.79M
FCVT First Trust SSI Strategic.. 0.00 % 0.95 %

N/A

USD0.29B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

N/A

USD0.16B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
XT iShares Exponential Techn.. 0.00 % 0.47 %

N/A

USD3.11B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.06 %

N/A

USD0.16B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD9.34M
QDVC:XETRA iShares Edge MSCI USA Siz.. 0.00 % 0.20 %

N/A

USD0.12B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.38% 10% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.38% 10% F 7% F
Trailing 12 Months  
Capital Gain -6.00% 40% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.00% 40% F 30% F
Trailing 5 Years  
Capital Gain -0.20% 49% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.20% 49% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain 2.44% 43% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.44% 42% F 41% F
Risk Return Profile  
Volatility (Standard Deviation) 16.61% 96% A 75% C
Risk Adjusted Return 14.71% 46% F 42% F
Market Capitalization 15.06B 98% A+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.20 36% F 53% F
Price/Book Ratio 3.67 62% D- 41% F
Price / Cash Flow Ratio 312.08 0% N/A 1% F
EV/EBITDA 122.40 6% F 7% F
Management Effectiveness  
Return on Equity 23.91% 98% A+ 93% A
Return on Invested Capital -0.76% 89% B+ 43% F
Return on Assets -0.80% 93% A 42% F
Debt to Equity Ratio 15.57% 53% F 69% D+
Technical Ratios  
Short Ratio 7.15 23% F 15% F
Short Percent 7.05% 47% F 30% F
Beta 0.71 83% B 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.